Phillips Medisize
Hudson, WI
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (10)
○ EMA GMP
○ MHRA GMP
Quick Facts: Phillips Medisize
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Hudson, WI
- Modalities
- Drug Delivery Devices (Autoinjectors, Pens, Patch Pumps), Inhalation Drug Delivery (DPI, MDI, Nebulizers, Nasal), Parenteral Drug Delivery Devices, Ocular Drug Delivery Devices, Combination Products, In Vitro Diagnostics (IVD), Medical Devices (CGM, Electrophysiology, Surgical Robotics)
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Phillips Medisize
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesDrug Delivery Devices (Autoinjectors, Pens, Patch Pumps), Inhalation Drug Delivery (DPI, MDI, Nebulizers, Nasal), Parenteral Drug Delivery Devices, Ocular Drug Delivery Devices, Combination Products, In Vitro Diagnostics (IVD), Medical Devices (CGM, Electrophysiology, Surgical Robotics)
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (7 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press10 articles
Broad modality coverage (7 modalities)
Recent News 10 articles
Tobacco firm PMI divests Vectura at a loss after backlash - pharmaphorum
Molex and Phillips Medisize win LEED Gold for new Poland campus - Medical Design & Outsourcing
Phillips-Medisize tapped to develop GlucoModicum's needle-free CGM - Fierce Biotech
Molex, a Parent to Phillips Medisize, Announces Agreement to Acquire the Vectura Group Limited, Expanding Its Drug Delivery Capabilities in Inhalation - Business Wire
Phillips Medisize Expands Its Inhalation Drug Delivery Capabilities - Business Wire
Layoffs Begin at Phillips-Medisize - PlasticsToday
ViCentra Scales Commercial Manufacturing, Triples Capacity and Strengthens Unit Economics - GlobeNewswire
ViCentra triples manufacturing capacity ahead of Kaleido rollout through Phillips Medisize collab - Drug Delivery Business
ViCentra Triples Insulin Pump Production, Eyeing European Expansion - BriefGlance
Phillips Medisize to Showcase Advances in Inhalation and Dry Powder Inhaler Innovations at Respiratory Drug Delivery (RDD) 2026 - Business Wire
Frequently Asked Questions About Phillips Medisize
What is Phillips Medisize's CDMO Signal Score?
Phillips Medisize has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Phillips Medisize for a manufacturing program?
Use the free AI matchmaker to compare Phillips Medisize against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.